A Pilot Study of Peptide Vaccines for VEGF Receptor 1 and 2 in Patients with Recurrent/progressive High Grade Glioma

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 May 17

PMID 29765561

Citations 12

Authors

Shunsuke Shibao

Ryo Ueda

Katsuya Saito

Ryogo Kikuchi

Hideaki Nagashima

Atsuhiro Kojima

Hiroshi Kagami

Eriel Sandika Pareira

Hikaru Sasaki

Shinobu Noji

Yutaka Kawakami

Kazunari Yoshida

Masahiro Toda

Affiliations

Soon will be listed here.

Abstract

Object: Early-phase clinical studies of glioma vaccines have shown feasibility and encouraging preliminary clinical activity. A vaccine that targets tumor angiogenesis factors in glioma microenvironment has not been reported. Therefore, we performed a pilot study to evaluate the safety and immunogenicity of a novel vaccination targeting tumor angiogenesis with synthetic peptides for vascular endothelial growth factor (VEGF) receptor epitopes in patients with recurrent/progressive high grade gliomas.

Methods: Eight patients received intranodal vaccinations weekly at a dose of 2mg/kg bodyweight 8 times. T-lymphocyte responses against VEGF receptor (VEGFR) epitopes were assessed by enzyme linked immunosorbent spot assays.

Results: This treatment was well-tolerated in patients. The first four vaccines induced positive immune responses against at least one of the targeted VEGFR epitopes in the peripheral blood mononuclear cells in 87.5% of patients. The median overall survival time in all patients was 15.9 months. Two achieved progression-free status lasting at least 6 months. Two patients with recurrent GBM demonstrated stable disease. Plasma IL-8 level was negatively correlated with overall survival.

Conclusion: These data demonstrate the safety and immunogenicity of VEGFR peptide vaccines targeting tumor vasculatures in high grade gliomas.

Citing Articles

Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.

Fei X, Wu J, Tian H, Jiang D, Chen H, Yan K Cancer Biomark. 2024; 41(1):1-24.

PMID: 39240627 PMC: 11492047. DOI: 10.3233/CBM-230486.

Tumor vaccines: Toward multidimensional anti-tumor therapies.

Tan Y, Chen H, Gou X, Fan Q, Chen J Hum Vaccin Immunother. 2023; 19(3):2271334.

PMID: 37905395 PMC: 10760370. DOI: 10.1080/21645515.2023.2271334.

Deciphering immune microenvironment and cell evasion mechanisms in human gliomas.

Rafii S, Kandoussi S, Ghouzlani A, Naji O, Reddy K, Sadiqi R Front Oncol. 2023; 13:1135430.

PMID: 37274252 PMC: 10235598. DOI: 10.3389/fonc.2023.1135430.

Tumor microenvironment antigens.

Andersen M Semin Immunopathol. 2022; 45(2):253-264.

PMID: 36175673 PMC: 10335965. DOI: 10.1007/s00281-022-00966-0.

Prognostic role of METTL1 in glioma.

Li L, Yang Y, Wang Z, Xu C, Huang J, Li G Cancer Cell Int. 2021; 21(1):633.

PMID: 34838021 PMC: 8627054. DOI: 10.1186/s12935-021-02346-4.

References

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K . Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012; 41(4):1297-304. DOI: 10.3892/ijo.2012.1573. View

Xie K . Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12(4):375-91. DOI: 10.1016/s1359-6101(01)00016-8. View

Brat D, Bellail A, Van Meir E . The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005; 7(2):122-33. PMC: 1871893. DOI: 10.1215/S1152851704001061. View

Phuphanich S, Wheeler C, Rudnick J, Mazer M, Wang H, Nuno M . Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2012; 62(1):125-35. PMC: 3541928. DOI: 10.1007/s00262-012-1319-0. View

Yoshimura K, Minami T, Nozawa M, Uemura H . Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer. 2013; 108(6):1260-6. PMC: 3619266. DOI: 10.1038/bjc.2013.90. View

Bloch O, Crane C, Fuks Y, Kaur R, Aghi M, Berger M . Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2013; 16(2):274-9. PMC: 3895386. DOI: 10.1093/neuonc/not203. View

Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N . Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012; 42(10):887-95. PMC: 3448378. DOI: 10.1093/jjco/hys121. View

10.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

11.

Raizer J, Grimm S, Chamberlain M, Nicholas M, Chandler J, Muro K . A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010; 116(22):5297-305. DOI: 10.1002/cncr.25462. View

12.

Neagu M, Reardon D . An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol. 2015; 16(11):54. DOI: 10.1007/s11864-015-0371-3. View

13.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J . A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512(7514):324-7. DOI: 10.1038/nature13387. View

14.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

15.

Niethammer A, Xiang R, Becker J, Wodrich H, Pertl U, Karsten G . A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002; 8(12):1369-75. DOI: 10.1038/nm1202-794. View

16.

Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-22. DOI: 10.1056/NEJMoa1308345. View

17.

Lu K, Chang J, Parachoniak C, Pandika M, Aghi M, Meyronet D . VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012; 22(1):21-35. PMC: 4068350. DOI: 10.1016/j.ccr.2012.05.037. View

18.

Beal K, Abrey L, Gutin P . Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011; 6:2. PMC: 3025871. DOI: 10.1186/1748-717X-6-2. View

19.

Sampson J, Archer G, Mitchell D, Heimberger A, Herndon 2nd J, Lally-Goss D . An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009; 8(10):2773-9. PMC: 2991139. DOI: 10.1158/1535-7163.MCT-09-0124. View

20.

Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M . Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res. 2005; 11(16):5900-11. DOI: 10.1158/1078-0432.CCR-05-0559. View